Mutations leading to constitutive activation of the kinase NIK in multiple myeloma have been found in NIK itself, that disrupts its binding with TRAF3, in turn causing dissociation of NIK from the inhibitory complex having TRAF2 and the ubiquitin ligases cIAP1 and cIAP2. This evidence concerns the gene MAP3K14 and plasma cell myeloma.